We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Akers Receives Cholesterol Test Kit Order from First Check
Read MoreHide Full Article
Developer of rapid health information technologies, Akers Biosciences, Inc. announced that it has received an initial order under the distribution agreement for its rapid cholesterol self-test kit from First Check Diagnostics, LLC.
Stock Performance
The price performance of the stock has been favorable in the last three months. Akers Biosciences returned 21.05%, outperforming the Zacks classified Medical Products sub-industry’s gain of almost 10.64%.
However, the estimate revision trend for the current year has been unfavorable as two estimates moved south in the last two months as against no movements in the opposite direction. Thus, investors are waiting for a reversal in estimates before adding the stock. This justifies the stock’s Zacks Rank #3 (Hold).
However, we are optimistic about continued advancements in Akers Biosciences’ innovative product pipeline that includes hassle-free rapid test solutions. Also, a long-term expected earnings growth rate of 12.27% and projected sales growth of 11.85% instill confidence in its investors.
Coming back to the news, Akers Biosciences’ distribution agreement with First Check is a smart move on the part of the company. This is because First Check sells its products through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo. Akers Bio's Tri-Cholesterol test kit is a combined rapid test which provides an estimate of a person's Total cholesterol as well as High Density Lipoprotein cholesterol levels. The test has already recieved FDA 510(k) clearance in the U.S. apart from a CE mark for the European Economic Area. The CE marking is the manufacturer's declaration that the product meets the requirements of the applicable European directives.
Moreover, per the US Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the U.S have high cholesterol and less than one in every three has the condition under control. By accessing First Check’s sales network, Akers Biosciences would be able to tap the target customer segment more effectively.
Akers Biosciences develops, manufactures and supplies rapid screening and testing products designed to deliver quicker and cost-effective healthcare information to consumers. We are impressed with the company’s innovative product pipeline that includes hassle-free rapid test solutions. Its efforts to ramp up PIFA Heparin sales in the U.S. and overseas through new distribution partnerships are also encouraging. We are also positive on sales in China (Novotek), meaningful contribution from the wellness platform and stringent cost control in all the key areas of business.
Inogen has a long-term expected earnings growth rate of 17.05%. Notably, the stock registered an impressive one-year return of 82%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company has a projected earnings per share growth rate of 39.53% for the current fiscal.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock reported a positive earnings surprise of 1.6% in the last reported quarter.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Akers Receives Cholesterol Test Kit Order from First Check
Developer of rapid health information technologies, Akers Biosciences, Inc. announced that it has received an initial order under the distribution agreement for its rapid cholesterol self-test kit from First Check Diagnostics, LLC.
.jpg)
Stock Performance
The price performance of the stock has been favorable in the last three months. Akers Biosciences returned 21.05%, outperforming the Zacks classified Medical Products sub-industry’s gain of almost 10.64%.
However, the estimate revision trend for the current year has been unfavorable as two estimates moved south in the last two months as against no movements in the opposite direction. Thus, investors are waiting for a reversal in estimates before adding the stock. This justifies the stock’s Zacks Rank #3 (Hold).
However, we are optimistic about continued advancements in Akers Biosciences’ innovative product pipeline that includes hassle-free rapid test solutions. Also, a long-term expected earnings growth rate of 12.27% and projected sales growth of 11.85% instill confidence in its investors.
Coming back to the news, Akers Biosciences’ distribution agreement with First Check is a smart move on the part of the company. This is because First Check sells its products through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo. Akers Bio's Tri-Cholesterol test kit is a combined rapid test which provides an estimate of a person's Total cholesterol as well as High Density Lipoprotein cholesterol levels. The test has already recieved FDA 510(k) clearance in the U.S. apart from a CE mark for the European Economic Area. The CE marking is the manufacturer's declaration that the product meets the requirements of the applicable European directives.
Moreover, per the US Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the U.S have high cholesterol and less than one in every three has the condition under control. By accessing First Check’s sales network, Akers Biosciences would be able to tap the target customer segment more effectively.
Akers Biosciences develops, manufactures and supplies rapid screening and testing products designed to deliver quicker and cost-effective healthcare information to consumers. We are impressed with the company’s innovative product pipeline that includes hassle-free rapid test solutions. Its efforts to ramp up PIFA Heparin sales in the U.S. and overseas through new distribution partnerships are also encouraging. We are also positive on sales in China (Novotek), meaningful contribution from the wellness platform and stringent cost control in all the key areas of business.
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corporation . Inogen sports a Zacks Rank #1 (Strong Buy) while Fluidigm and Avinger carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inogen has a long-term expected earnings growth rate of 17.05%. Notably, the stock registered an impressive one-year return of 82%.
Avinger projects sales growth of 30.6% for the current year. Additionally, the company has a projected earnings per share growth rate of 39.53% for the current fiscal.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock reported a positive earnings surprise of 1.6% in the last reported quarter.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>